Equities Analysts Issue Forecasts for Korro Bio Q3 Earnings

Key Points

• HC Wainwright has revised Korro Bio's Q3 2025 EPS estimate downward from ($1.88) to ($2.43), while maintaining a "Buy" rating with a $90.00 price target.
• In its latest quarterly earnings report, Korro Bio reported an EPS of ($2.74), missing estimates, but exceeded revenue expectations with $1.46 million against a forecast of $0.41 million.
• Korro Bio has received mixed reviews from analysts; while five have given a buy rating, others have reduced their price targets significantly, with the average target now at $86.83.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities researchers at HC Wainwright cut their Q3 2025 EPS estimates for shares of Korro Bio in a report released on Wednesday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.43) for the quarter, down from their previous estimate of ($1.88). HC Wainwright has a "Buy" rating and a $90.00 price target on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio's Q4 2025 earnings at ($2.26) EPS, FY2025 earnings at ($9.93) EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.28) EPS, Q3 2026 earnings at ($2.34) EPS, Q4 2026 earnings at ($2.39) EPS and FY2026 earnings at ($9.23) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($2.74) EPS for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The firm had revenue of $1.46 million during the quarter, compared to analyst estimates of $0.41 million.

A number of other analysts have also issued reports on KRRO. Cantor Fitzgerald upgraded shares of Korro Bio to a "strong-buy" rating in a research note on Tuesday, April 29th. Oppenheimer dropped their price objective on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Chardan Capital reiterated a "buy" rating and set a $25.00 target price on shares of Korro Bio in a report on Wednesday. Finally, Raymond James Financial decreased their price target on shares of Korro Bio from $153.00 to $147.00 and set a "strong-buy" rating for the company in a research report on Wednesday. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Korro Bio currently has an average rating of "Buy" and a consensus target price of $86.83.

Korro Bio Trading Up 5.0%

KRRO opened at $19.88 on Friday. The stock's 50-day moving average price is $14.20 and its 200 day moving average price is $18.23. Korro Bio has a 12-month low of $10.29 and a 12-month high of $98.00. The firm has a market cap of $186.67 million, a price-to-earnings ratio of -2.04 and a beta of 2.51.

Institutional Trading of Korro Bio

Hedge funds have recently added to or reduced their stakes in the company. Balyasny Asset Management L.P. acquired a new position in Korro Bio during the 4th quarter worth approximately $220,000. Legal & General Group Plc raised its holdings in shares of Korro Bio by 664.1% in the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after purchasing an additional 3,759 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Korro Bio by 128,950.0% during the 1st quarter. GAMMA Investing LLC now owns 10,324 shares of the company's stock worth $180,000 after purchasing an additional 10,316 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock worth $156,000 after purchasing an additional 935 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Korro Bio by 9.0% during the first quarter. Bank of New York Mellon Corp now owns 16,113 shares of the company's stock worth $281,000 after purchasing an additional 1,325 shares in the last quarter. Institutional investors and hedge funds own 13.18% of the company's stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.